01 吉利德科学公司的新型HIV抗病毒药物来那帕韦 (lenacapavir)在第二个关键3期临床试验中显示出99.9%的受试者未感染HIV，一年两次给药的治疗方案解决了HIV感染者需要终身服药的问题。

The drug, lenacapavir PrEP, could benefit tens of millions of people at high risk of infection The post ACT UP London protest ...

吉利德科学公司（NASDAQ:GILD）在竞争对手临床试验受挫后，继续保持其在肿瘤市场的强劲地位。全球投资银行公司Jefferies重申了对吉利德科学公司的信心，给予"买入"评级，目标价格维持在95.00美元。

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

There are now multiple forms of injectable PrEP medications. Lenacapavir, which is Gilead's injectable drug, differs from ...

Discover the latest updates on the Global Fund's efforts in combating AIDS, Tuberculosis, and Malaria amidst challenges posed ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Peter Sands, head of the Global Fund, warned that climate change and conflict could undermine health improvements. Despite progress, funding concerns persist for 2026-2028 efforts. The 2024 report ...

Twice-yearly lenacapavir was found to be superior to daily emtricitabine 200mg and tenofovir disoproxil fumarate 300mg.

The process for translating clinical trial results into action for young women in Africa has been left to our imaginations, ...

Granting patents to US firm Gilead Sciences for lenacapavir could hinder global efforts to end AIDS & restrict access to ...

It could be a real breakthrough for people at risk for HIV infection: A shot given every 6 months that reduces their risk by a whopping 96%.